This blog is related to the various litigations related to patents w.r.t pharma industry.
Tuesday, July 21, 2009
FDA Approves Tekturna HCT as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
The US FDA has approved Tekturna HCT (aliskiren and hydrochlorothiazide) tablets as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure goals.
No comments:
Post a Comment